Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated (NYSE: DGX) is a medical laboratories company focused on diagnostic testing and diagnostic information services, and its news flow reflects its role across the healthcare ecosystem. The company regularly issues updates on its financial reporting schedule, including announcements about quarterly and full-year results and related conference calls, which are of interest to investors tracking DGX stock and performance trends.
News about Quest Diagnostics also covers participation in major healthcare and investor conferences. For example, the company has announced presentations at events such as the J.P. Morgan Healthcare Conference and Citi’s Global Healthcare Conference, where its leadership discusses strategy, performance and market developments. These appearances provide insight into how the company views its position in the diagnostic testing and information services market.
Quest Diagnostics’ news includes information on collaborations and joint ventures that expand access to laboratory services. Announcements have highlighted a laboratory services joint venture with Corewell Health in Michigan, as well as the ongoing role of Sonora Quest Laboratories, an Arizona-based joint venture between Banner Health and Quest Diagnostics. Such items help readers understand how Quest Diagnostics partners with health systems to deliver regional laboratory services and hospital lab management solutions.
In addition, Quest Diagnostics reports on developments in specialized diagnostics through subsidiaries and collaborations. News has featured Haystack MRD, a minimal residual disease test developed by Haystack Oncology, a wholly owned subsidiary of Quest Diagnostics, including data presentations at scientific meetings and clinical research collaborations. Other coverage has described a strategic collaboration with Octave Bioscience to expand access to the Octave Multiple Sclerosis Disease Activity Test through Quest’s specimen-collection network.
Visitors to the DGX news page can review these types of updates to follow financial communications, strategic partnerships, scientific data presentations and corporate announcements that shape Quest Diagnostics’ activities in the medical laboratories sector.
Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.66 per share, scheduled for payment on July 20, 2022. Shareholders of record as of July 6, 2022 will receive this dividend. This distribution reflects the company’s commitment to returning value to its investors.
Quest Diagnostics is a leader in diagnostic services, serving one in three adult Americans and half of U.S. physicians and hospitals. Its insights aim to improve health outcomes and healthcare management.
Quest Diagnostics (NYSE: DGX) will present at the UBS 2022 Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET. CEO Steve Rusckowski and CEO-elect Jim Davis will discuss the company's vision and capital strategies. The event will be available via live webcast on the company's investor relations page and archived for later viewing until June 23, 2022. Quest Diagnostics is a leader in diagnostic information services, supporting health improvements for a significant portion of the U.S. population.
Summary not available.
Quest Diagnostics has introduced a blood test, QUEST AD-Detect™, to assess the risk of Alzheimer's Disease (AD), amidst rising optimism among physicians and patients for advancements in AD diagnostics and treatment. A recent survey showed 66% of physicians anticipate groundbreaking therapies, with 84% believing early risk testing will enhance disease management. However, cost concerns may hinder widespread adoption. Despite this, 87% of physicians think the blood test will become a standard practice, highlighting an evolving landscape in AD healthcare.
Quest Diagnostics (DGX) reported Q1 2022 revenues of $2.61 billion, a 4.0% decline compared to 2021. Reported diluted EPS was $2.92, down 15.6%, while adjusted diluted EPS was $3.22, a drop of 14.4%. Base business revenues rose 6.3% to $2.01 billion. Despite COVID-19 testing revenue decreasing 27.6% to $599 million, full-year guidance was raised. The new diluted EPS guidance ranges from $7.88 to $8.38, with adjusted EPS expected between $9.00 and $9.50.
Quest Diagnostics (NYSE: DGX) announced key organizational changes to enhance operational efficiency and growth. Catherine T. Doherty has been appointed Senior VP for Regional Businesses, while Carrie E. Eglinton Manner takes on Senior VP for Advanced & General Diagnostics Clinical Solutions. Patrick T. Plewman is now Senior VP for Diagnostic Services, and Mark E. Delaney joins as Chief Commercial Officer. Additionally, Richard F. Adams steps in as VP and GM for Consumer Initiated Testing. The company aims to improve strategy execution and strengthen its leadership team.
Quest Diagnostics has announced a collaboration with IRIS to offer diabetic retinal imaging services at its patient service centers across the United States. This initiative aims to enhance access to screenings for diabetic retinopathy, a leading cause of blindness, particularly for patients identified as high-risk by participating health plans. The collaboration is designed to improve screening rates and health outcomes by enabling early detection and treatment. Training for Quest personnel will ensure images are sent to licensed ophthalmologists for evaluation.
Quest Diagnostics (NYSE: DGX) will announce its first quarter 2022 financial results on April 21, 2022, before market opening. A conference call to discuss the results is scheduled at 8:30 a.m. ET. Interested parties can access the call by dialing 888-455-0391 (U.S. and Canada) or 773-756-0467 (international), using the passcode '7895081'. A replay will be available until May 5, 2022. For further information, visit QuestDiagnostics.com/investor.
Quest Diagnostics reported a significant rise in drug test positivity rates in the U.S. workforce, reaching the highest levels since 2001. The overall positivity rate for urine tests increased to 4.6% in 2021, up 31.4% from an all-time low in 2010-2012. Notably, federally mandated safety-sensitive workers' positivity remained steady at 2.2%. Marijuana positivity in the general workforce rose to 3.9%, marking a 50% increase over five years. Employers face challenges in recruitment while ensuring workplace safety amidst these trends.
Quest Diagnostics (NYSE: DGX) has secured a $19.5 million contract from the Centers for Disease Control and Prevention (CDC) to provide COVID-19 antibody testing and data analytics services across 45 states and Puerto Rico. The contract aims to assist the CDC in understanding SARS-CoV-2 seroprevalence, evaluating the population proportion infected or vaccinated. Quest will utilize clinical testing serum remnants to enhance public health analysis and reporting, demonstrating its ongoing commitment to effective pandemic response.